Zyprexa Lawsuit Web Log | |
Monheit Law: Vioxx: Lawyers for Vioxx Lawsuits Zyprexa Lawyer Web Log Archived Zyprexa Articles Current Zyprexa Articles Ask Monheit Law, "Do I have a Zyprexa Case?" Zyprexa Medical Information Zyprexa side effect Information
|
Monheit Law: Vioxx: Lawyers for Vioxx Lawsuits : Zyprexa Lawyer Web Log : 2004-12-14 : Article
Welcome to Zyprexa Lawyer Information
Zyprexa is an atypical antipsychotic drug for treating schizophrenia and related psychotic disorders. If you or a someone you know has suffered serious injury from Zyprexa in the state of Nevada, we can help.
Monheit Law: Zyprexa Side Effects Lawsuits
Eli Lilly and Company has warned about important labeling changes regarding Zyprexa (olanzapine). The Food and Drug Administration (FDA) has asked all manufacturers of atypical antipsychotic medications, including Lilly, to add a Warning statement describing the increased risk of hyperglycemia and diabetes in patients taking these medications, including Zyprexa. In addition to Zyprexa, the atypical antipsychotic class includes Clozaril ? (clozapine, Novartis), Risperdal ? (risperidone, Janssen), Seroquel ? (quetiapine, AstraZeneca), Geodon ? (ziprasidone, Pfizer), and Abilify ? (aripiprazole, Bristol Myers Squibb and Otsuka American Pharmaceutical). Accordingly, the Zyprexa prescribing information has been updated with the following information:
ZYPREXA WARNINGS
Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics including Zyprexa. Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of diabetes mellitus in patients with schizophrenia and the increasing incidence of diabetes mellitus in the general population. Given these confounders, the relationship between atypical antipsychotic use and hyperglycemia-related adverse events is not completely understood. However, epidemiological studies suggest an increased risk of treatment-emergent hyperglycemia-related adverse events in patients treated with the atypical antipsychotics. Precise risk estimates for hyperglycemia related adverse events in patients treated with atypical antipsychotics are not available.
Patients with an established diagnosis of diabetes mellitus who are started on atypical antipsychotics should be monitored regularly for worsening of glucose control. Patients with risk factors for diabetes mellitus (e.g., obesity, family history of diabetes) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug.
Should you have any questions or concerns regarding this important safety information, please contact your Eli Lilly and Company sales representative or contact the Lilly medical department at 1-800-Lilly-Rx . Please refer to the full prescribing information for Zyprexa included with this letter. As always, we request that serious adverse events be reported to Lilly at 1-800-Lilly-Rx or to the FDA MedWatch program by phone (1-800-FDA-1088 ), by fax (1-800-FDA-0178 ) or by email (www.fda.gov/medwatch).
Helping the families and victims of unsafe prescription drugs.
The FDA has asked the manufacturer of Zyprexa, Eli Lilly and Company, and other manufactures of atypical antipsychotic medications, to add a Warning statement describing the risks of hyperglycemia and diabetes in patients taking these medications.
Zyprexa is manufactured by Eli Lilly and is prescribed for schizophrenia and bipolar mania. So far this top selling drug has been linked to more than 380 cases of sugar disorder, from which 23 people have died. The FDA has recently requested Eli Lilly to add a more direct warning label to Zyprexa indicating its serious side effects.
|
Home | Site Map | Disclaimer